Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Nowotwory. Journal of Oncology
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Editorial Office Manuscript Submission Reviewers 2023 Best Original Paper Award

open access

Vol 72, No 4 (2022)
Review paper
Published online: 2022-05-25
View PDF Download PDF file
Get Citation

Principles of prevention and management of adverse events of immunomodulatory drugs in the treatment of multiple myeloma

Grzegorz Charliński1, David H. Vesole23, Artur Jurczyszyn4
DOI: 10.5603/NJO.a2022.0031
·
Nowotwory. Journal of Oncology 2022;72(4):231-241.
Affiliations
  1. Department of Hematology, Medical Faculty, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland
  2. Department of Hematology/Oncology, Medstar Georgetown University Hospital, Washington, United States
  3. John Theurer Cancer Center at Hackensack Meridian School of Medicine, Hackensack, United States
  4. Plasma Cell Dyscrasias Center, Department of Hematology, Faculty of Medicine, Jagiellonian University Medical College, Krakow, Poland

open access

Vol 72, No 4 (2022)
Review article
Published online: 2022-05-25

Abstract

Over the past 15 years, significant progress has been made in understanding the biology and treatment of multiple myeloma (MM). This is due to the introduction of new therapies and new applications of known drugs associated with a better understanding of how to optimize treatment to patient and disease characteristics. Indeed, 15 new drugs have been approved over this time period. Immunomodulatory drugs (IMiDs) have been used in the treatment of MM for over 20 years. Initially, it was thalidomide, then analogues lenalidomide and pomalidomide; in the future, cereblon E3 ligase modulators CelMoDs, such as iberdomide and CC-480. Currently, IMiDs are mainly used as the backbone of multi­-drug protocols, including in combination with monoclonal antibodies and proteasome inhibitors. Given the common utilization of IMiDs in the management of MM, it is relevant to review the safety profile of IMiDs and the management of adverse events (AEs).

Abstract

Over the past 15 years, significant progress has been made in understanding the biology and treatment of multiple myeloma (MM). This is due to the introduction of new therapies and new applications of known drugs associated with a better understanding of how to optimize treatment to patient and disease characteristics. Indeed, 15 new drugs have been approved over this time period. Immunomodulatory drugs (IMiDs) have been used in the treatment of MM for over 20 years. Initially, it was thalidomide, then analogues lenalidomide and pomalidomide; in the future, cereblon E3 ligase modulators CelMoDs, such as iberdomide and CC-480. Currently, IMiDs are mainly used as the backbone of multi­-drug protocols, including in combination with monoclonal antibodies and proteasome inhibitors. Given the common utilization of IMiDs in the management of MM, it is relevant to review the safety profile of IMiDs and the management of adverse events (AEs).

Full Text:

View PDF Download PDF file
Get Citation

Keywords

adverse events; immunomodulatory drugs; lenalidomide; management; multiple myeloma; pomalidomide; thalidomide; treatment

About this article
Title

Principles of prevention and management of adverse events of immunomodulatory drugs in the treatment of multiple myeloma

Journal

Nowotwory. Journal of Oncology

Issue

Vol 72, No 4 (2022)

Article type

Review paper

Pages

231-241

Published online

2022-05-25

Page views

3783

Article views/downloads

373

DOI

10.5603/NJO.a2022.0031

Bibliographic record

Nowotwory. Journal of Oncology 2022;72(4):231-241.

Keywords

adverse events
immunomodulatory drugs
lenalidomide
management
multiple myeloma
pomalidomide
thalidomide
treatment

Authors

Grzegorz Charliński
David H. Vesole
Artur Jurczyszyn

References (85)
  1. Usmani SZ, Hoering A, Cavo M, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project. Blood Cancer J. 2018; 8(12): 123.
    CrossRefPubMed
  2. Aragon-Ching JB, Li H, Gardner ER, et al. Thalidomide analogues as anticancer drugs. Recent Pat Anticancer Drug Discov. 2007; 2(2): 167–174.
    CrossRefPubMed
  3. Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev. 2010; 24 Suppl 1: S13–S19.
    CrossRefPubMed
  4. Ito T, Ando H, Handa H, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010; 327(5971): 1345–1350.
    CrossRefPubMed
  5. Ito T, Handa H. Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs. Int J Hematol. 2016; 104(3): 293–299.
    CrossRefPubMed
  6. Sievers QL, Petzold G, Bunker RD, et al. Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN. Science. 2018; 362(6414).
    CrossRefPubMed
  7. Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014; 343(6168): 305–309.
    CrossRefPubMed
  8. John LB, Ward AC. The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. Mol Immunol. 2011; 48(9-10): 1272–1278.
    CrossRefPubMed
  9. Chanan-Khan AA, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013; 3: e143.
    CrossRefPubMed
  10. Castelli R, Cassin R, Cannavò A, et al. Immunomodulatory drugs: new options for the treatment of myelodysplastic syndromes. Clin Lymphoma Myeloma Leuk. 2013; 13(1): 1–7.
    CrossRefPubMed
  11. Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood. 2001; 98(1): 210–216.
    CrossRefPubMed
  12. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol. 2005; 128(2): 192–203.
    CrossRefPubMed
  13. Noonan K, Rudraraju L, Ferguson A, et al. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res. 2012; 18(5): 1426–1434.
    CrossRefPubMed
  14. Matyskiela ME, Zhang W, Man HW, et al. A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos. J Med Chem. 2018; 61(2): 535–542.
    CrossRefPubMed
  15. Hansen JD, Correa M, Nagy MA, et al. Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma. J Med Chem. 2020; 63(13): 6648–6676.
    CrossRefPubMed
  16. Moreau P, San Miguel J, Sonneveld P, et al. ESMO Guidelines Committee. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv52–iv61.
    CrossRefPubMed
  17. Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999; 341(21): 1565–1571.
    CrossRefPubMed
  18. Richardson PG, Delforge M, Beksac M, et al. Management of treatment-emergent peripheral neuropathy in multiple myeloma. Leukemia. 2012; 26(4): 595–608.
    CrossRefPubMed
  19. https://www.gov.pl/web/zdrowie/choroby-onkologiczne (15.03.2022).
  20. Lacy MQ, McCurdy AR. Pomalidomide. Blood. 2013; 122(14): 2305–2309.
    CrossRefPubMed
  21. Quach H, Ritchie D, Stewart AK, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010; 24(1): 22–32.
    CrossRefPubMed
  22. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf (25.11.2021).
  23. Ghobrial IM, Rajkumar SV. Management of thalidomide toxicity. J Support Oncol. 2003; 1(3): 194–205.
    PubMed
  24. Dimopoulos MA, Moreau P, Terpos E, et al. EHA Guidelines Committee. Electronic address: guidelines@ehaweb.org, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(3): 309–322.
    CrossRefPubMed
  25. Cohen AD, Parekh S, Santomasso BD, et al. KEYNOTE-183 Investigators. Management of treatment-related adverse events in patients with multiple myeloma. Cancer Treat Rev. 2010; 36 Suppl 2(4): S24–S32.
    CrossRefPubMed
  26. Cavo M, Pantani L, Petrucci MT, et al. GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) Italian Myeloma Network. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012; 120(1): 9–19.
    CrossRefPubMed
  27. Moreau P, Hulin C, Macro M, et al. VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial. Blood. 2016; 127(21): 2569–2574.
    CrossRefPubMed
  28. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019; 394(10192): 29–38.
    CrossRefPubMed
  29. Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 2011; 25(4): 689–696.
    CrossRefPubMed
  30. Palumbo A, Waage A, Hulin C, et al. Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013; 98(1): 87–94.
    CrossRefPubMed
  31. Morgan GJ, Davies FE, Gregory WM, et al. National Cancer Research Institute Haematological Oncology Clinical Studies Group. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012; 97(3): 442–450.
    CrossRefPubMed
  32. Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial. Blood. 2013; 121(9): 1517–1523.
    CrossRefPubMed
  33. Donk Nv, Holt Bv, Minnema M, et al. Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial. The Lancet Haematology. 2018; 5(10): e479–e492.
    CrossRef
  34. Glasmacher A, Hahn C, Hoffmann F, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol. 2006; 132(5): 584–593.
    CrossRefPubMed
  35. Terpos E, Christoulas D, Kastritis E, et al. Greek Myeloma Study Group. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol. 2001; 12(7): 991–995.
    CrossRefPubMed
  36. Kropff MH, Lang N, Bisping G, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol. 2003; 122(4): 607–616.
    CrossRefPubMed
  37. Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008; 111(8): 3968–3977.
    CrossRefPubMed
  38. Schiff D, Wen PY, van den Bent MJ. Neurological adverse effects caused by cytotoxic and targeted therapies. Nat Rev Clin Oncol. 2009; 6(10): 596–603.
    CrossRefPubMed
  39. Reddy GK, Mughal TI, Lonial S. Optimizing the management of treatment-related peripheral neuropathy in patients with multiple myeloma. Support Cancer Ther. 2006; 4(1): 19–22.
    CrossRefPubMed
  40. Tariman JD, Love G, McCullagh E, et al. IMF Nurse Leadership Board. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs. 2008; 12(3 Suppl): 29–36.
    CrossRefPubMed
  41. Jongen JL, Broijl A, Sonneveld P. Chemotherapy-induced peripheral neuropathies in hematological malignancies. J Neurooncol. 2015; 121(2): 229–237.
    CrossRefPubMed
  42. Delforge M, Bladé J, Dimopoulos MA, et al. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010; 11(11): 1086–1095.
    CrossRefPubMed
  43. Palumbo A, Palladino C. Venous and arterial thrombotic risks with thalidomide: evidence and practical guidance. Ther Adv Drug Saf. 2012; 3(5): 255–266.
    CrossRefPubMed
  44. Snowden JA, Ahmedzai SH, Ashcroft J, et al. Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum. Guidelines for supportive care in multiple myeloma 2011. Br J Haematol. 2011; 154(1): 76–103.
    CrossRefPubMed
  45. Minnema MC, Breitkreutz I, Auwerda JJA, et al. Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia. 2004; 18(12): 2044–2046.
    CrossRefPubMed
  46. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22(2): 414–423.
    CrossRefPubMed
  47. Fouquet G, Bories C, Guidez S, et al. Pomalidomide for multiple myeloma. Expert Rev Hematol. 2014; 7(6): 719–731.
    CrossRefPubMed
  48. NCCN Clinical Practice Guidelines in Oncology. Multiple myeloma. Version 4.2022.
  49. Smith LC, Bertolotti P, Curran K, et al. IMF Nurse Leadership Board. Gastrointestinal side effects associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs. 2008; 12(3 Suppl): 37–52.
    CrossRefPubMed
  50. Dimopoulos MA, Roussou M, Gkotzamanidou M, et al. The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Leukemia. 2013; 27(2): 423–429.
    CrossRefPubMed
  51. Rizzello I, Cavo M, Dozza L, et al. GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto Italian Myeloma Network), GIMEMA Italian Myeloma Network. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol. 2004; 73(2): 98–103.
    CrossRefPubMed
  52. Alexander M, Kirsa S, Mellor JD. Thalidomide thromboprophylaxis in multiple myeloma: a review of current evidence. Asia Pac J Clin Oncol. 2012; 8(4): 319–324.
    CrossRefPubMed
  53. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood. 2008; 111(3): 1101–1109.
    CrossRefPubMed
  54. Rajkumar SV, Jacobus S, Callander NS, et al. Eastern Cooperative Oncology Group. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010; 11(1): 29–37.
    CrossRefPubMed
  55. Morgan GJ, Schey SA, Wu P, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol. 2007; 137(3): 268–269.
    CrossRefPubMed
  56. Schey S, Morgan G, Ramasamy K, et al. CRD: A Phase 1 Dose Escalation Study to Determine the Maximum Tolerated Dose of Cyclophosphamide in Combination with Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma. Blood. 2008; 112(11): 3707–3707.
    CrossRef
  57. Facon T, Dimopoulos MA, Dispenzieri A, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018; 131(3): 301–310.
    CrossRefPubMed
  58. Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017; 389(10068): 519–527.
    CrossRefPubMed
  59. Facon T, Kumar S, Plesner T, et al. MAIA Trial Investigators. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. N Engl J Med. 2019; 380(22): 2104–2115.
    CrossRefPubMed
  60. Palumbo A, Gay F, Cavallo F, et al. MM-015 Investigators. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012; 366(19): 1759–1769.
    CrossRefPubMed
  61. Dimopoulos M, Spencer A, Attal M, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007; 357(21): 2123–2132.
    CrossRefPubMed
  62. Weber DM, Chen C, Niesvizky R, et al. Multiple Myeloma (009) Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007; 357(21): 2133–2142.
    CrossRefPubMed
  63. Stewart AK, Rajkumar SV, Dimopoulos MA, et al. ASPIRE Investigators. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015; 372(2): 142–152.
    CrossRefPubMed
  64. Mateos MV, Masszi T, Grzasko N, et al. TOURMALINE-MM1 Study Group. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016; 374(17): 1621–1634.
    CrossRefPubMed
  65. Bahlis NJ, Dimopoulos MA, White DJ, et al. Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia. 2020; 34(7): 1875–1884.
    CrossRefPubMed
  66. Dimopoulos MA, Lonial S, White D, et al. Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth. Br J Haematol. 2017; 178(6): 896–905.
    CrossRefPubMed
  67. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008; 22(2): 414–423.
    CrossRefPubMed
  68. https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf (25.11.2021).
  69. Richardson P, Jagannath S, Hussein M, et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood. 2009; 114(4): 772–778.
    CrossRefPubMed
  70. Imbesi S, Allegra A, Calapai G, et al. Cutaneous adverse reactions to lenalidomide. Allergol Immunopathol (Madr). 2015; 43(1): 88–91.
    CrossRefPubMed
  71. Barley K, He W, Agarwal S, et al. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma. Leuk Lymphoma. 2016; 57(11): 2510–2515.
    CrossRefPubMed
  72. Tinsley SM, Kurtin SE, Ridgeway JA. Practical Management of Lenalidomide-Related Rash. Clin Lymphoma Myeloma Leuk. 2015; 15 Suppl: S64–S69.
    CrossRefPubMed
  73. Vehreschild MJ, Vehreschild JJ, Hübel K, et al. German Society of Hematology and Oncology. Diagnosis and management of gastrointestinal complications in adult cancer patients: evidence-based guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Oncol. 2013; 24(5): 1189–1202.
    CrossRefPubMed
  74. Pawlyn C, Khan MS, Muls A, et al. Lenalidomide-induced diarrhea in patients with myeloma is caused by bile acid malabsorption that responds to treatment. Blood. 2014; 124(15): 2467–2468.
    CrossRefPubMed
  75. Richardson PG, Palumbo A, Schey SA, et al. Pomalidomide – an appraisal of its clinical development and role in the treatment of relapsed/refractory multiple myeloma. Eur Oncol Haematol. 2015; 11: 109–117.
  76. Miguel J, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013; 14(11): 1055–1066.
    CrossRef
  77. Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016; 128(4): 497–503.
    CrossRefPubMed
  78. Richardson PG, Oriol A, Beksac M, et al. OPTIMISMM trial investigators. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(6): 781–794.
    CrossRefPubMed
  79. Dimopoulos MA, Terpos E, Boccadoro M, et al. APOLLO Trial Investigators. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(6): 801–812.
    CrossRefPubMed
  80. Attal M, Richardson PG, Rajkumar SV, et al. ICARIA-MM study group. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019; 394(10214): 2096–2107.
    CrossRefPubMed
  81. Dimopoulos MA, Dytfeld D, Grosicki S, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. N Engl J Med. 2018; 379(19): 1811–1822.
    CrossRefPubMed
  82. Richardson PG, Siegel DS, Vij R, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014; 123(12): 1826–1832.
    CrossRefPubMed
  83. Dimopoulos MA, Leleu X, Palumbo A, et al. Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma. Leukemia. 2014; 28(8): 1573–1585.
    CrossRefPubMed
  84. https://www.ema.europa.eu/en/documents/product-information/imnovid-epar-product-information_en.pdf (25.11.2021).
  85. Dimopoulos M, Weisel K, van de Donk NW, et al. Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. J Clin Oncol. 2018; 36(20): 2035–2043.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl